Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SYRE
    4. >
  4. Valuation

Valuation

-
stocks logo
SYRE
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

Is SYRE Overvalued？

SYRE is now in the zone, suggesting that SYRE current forward PE ratio of -5.91 is considered compare with the five-year average of -4.79.
P/E
EV/EBITDA
P/S
P/B
P/E
bubble
P/E

SYRE Competitors Valuation Multiple

P/E
EV/EBITDA
P/S
P/E

P/E Multiple

Earnings Growth
Market Cap
stocks logo
SYRE.O
Spyre Therapeutics Inc
loss
Average P/E:
85.48%
1.35B
stocks logo
ARVN.O
Arvinas Inc
loss
Average P/E:
42.32%
1.21B
stocks logo
ANIP.O
ANI Pharmaceuticals Inc
loss
Average P/E:
-379.89%
1.23B
stocks logo
SNDX.O
Syndax Pharmaceuticals Inc
loss
Average P/E:
-34.49%
1.21B
stocks logo
RCUS.N
Arcus Biosciences Inc
loss
Average P/E:
-5.76%
1.18B
stocks logo
OPT.O
Opthea Ltd
loss
Average P/E:
855.72M

SYRE Revenue Breakdown & PS Ratio Relation

By Business
By Region
Currency:USD
Composition ()
Name
Revenue
Percentage

SYRE FAQs

Is SYRE currently overvalued based on its P/E ratio?

According to the provided data, SYRE's 5-year historical average forward P/E ratio is -4.79. SYRE forward P/E ratio is -5.91, which is categorized as Fair.

How has SYRE's P/E ratio changed over the quarters?

The P/E ratio has shown significant fluctuations, with a notable decrease from 2.16 to 1.73, indicating changes in market expectations and earnings.

What is the significance of the EV/EBITDA ratio for SYRE?

The EV/EBITDA ratio helps assess the company's valuation relative to its earnings before interest, taxes, depreciation, and amortization, providing a clearer picture of its operating performance.

What are the key indicators to watch for SYRE's financial performance?

Key indicators include valuation ratios (P/E, EV/EBITDA, P/FCF), revenue growth, and profitability metrics to assess overall financial health.

SYRE PE Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
5Y Average PE
-4.79
Current PE
-5.91
Overvalued PE
-1.71
Undervalued PE
-7.87

SYRE EV/EBITDA Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
5Y Average EV
-2.01
Current EV
-5.19
Overvalued EV
0.68
Undervalued EV
-4.70

SYRE P/S Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
5Y Average PS
162.71
Current PS
154.28
Overvalued PS
546.05
Undervalued PS
-220.64

SYRE Competitors Valuation Multiple

P/E
EV/EBITDA
P/S
P/E

P/E Multiple

Earnings Growth
Market Cap
stocks logo
SYRE.O
Spyre Therapeutics Inc
loss
Average P/E:
85.48%
1.35B
stocks logo
ARVN.O
Arvinas Inc
loss
Average P/E:
42.32%
1.21B
stocks logo
ANIP.O
ANI Pharmaceuticals Inc
loss
Average P/E:
-379.89%
1.23B
stocks logo
SNDX.O
Syndax Pharmaceuticals Inc
loss
Average P/E:
-34.49%
1.21B
stocks logo
RCUS.N
Arcus Biosciences Inc
loss
Average P/E:
-5.76%
1.18B
stocks logo
OPT.O
Opthea Ltd
loss
Average P/E:
855.72M

SYRE Revenue Breakdown & PS Ratio Relation

By Business
By Region
Currency:USD
Composition ()
Name
Revenue
Percentage

Free Financial AI Agent for Investment

Ask any investment related question and get answer instantly

At what price is SYRE undervalued？Is SYRE overvalued compared to its competitors？

SYRE FAQs

Is SYRE currently overvalued based on its P/E ratio?

According to the provided data, SYRE's 5-year historical average forward P/E ratio is -4.79. SYRE forward P/E ratio is -5.91, which is categorized as Fair.

How has SYRE's P/E ratio changed over the quarters?

The P/E ratio has shown significant fluctuations, with a notable decrease from 2.16 to 1.73, indicating changes in market expectations and earnings.

What is the significance of the EV/EBITDA ratio for SYRE?

The EV/EBITDA ratio helps assess the company's valuation relative to its earnings before interest, taxes, depreciation, and amortization, providing a clearer picture of its operating performance.

What are the key indicators to watch for SYRE's financial performance?

Key indicators include valuation ratios (P/E, EV/EBITDA, P/FCF), revenue growth, and profitability metrics to assess overall financial health.

Free Financial AI Agent for Investment

Ask any investment related question and get answer instantly

At what price is SYRE undervalued？Is SYRE overvalued compared to its competitors？
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free